Biopolym. Cell. 2015; 31(3):209-217.
Molecular Biomedicine
Cisplatin treatment of C6 rat glioma in vivo did not influence copy number alterations and growth pattern of tumor-derived resistant cells
1Stepanenko A. A., 2, 3Baklaushev V. P., 4Vassetzky Y. S., 1Dmitrenko V. V.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
  2. Pirogov Russian National Research Medical University
    1, Ostrovitianov Str., Moscow, Russian Federation, 117997
  3. Federal Research and Clinical Centre, Federal Medical-Biological Agency
    28, Orekhovy Blvd, Moscow, Russian Federation, 115682
  4. CNRS UMR 8126, Universit Paris-Sud 11, Institut Gustave Roussy
    114, rue Edouard Vaillant, Villejuif, France, 94805


Aim. To investigate whether the cisplatin treatment of C6 rat glioma in vivo impacts the copy number alterations (CNAs), proliferation and colony formation efficiency (CFE) of tumor-derived cisplatin-resistant cells. Methods. The glioma modeling was performed by means of intracerebral stereotactic implantation of rat glioma C6 cells into the striatum region of rats. The rats received 20 % dimethyl sulfoxide DMSO (C6R1) or cisplatin (C6R4CIS and C6R5CIS) injected intraperitoneally (5 mg/kg) three times per week. After 10 injections, gliomas were resected and the cells were cultured for in vitro analysis. CNAs were analyzed by array comparative genome hybridization, proliferation by direct cell counting in hemocytometer, CFE by soft agar assay. Results. No significant changes in the CNAs and CFE of cisplatin-treated rat glioma C6R4CIS and C6R5CIS cell lines were observed compared to the vehicle-treated control C6R1 cells. However, C6R5CIS but not C6R4CIS had a reduced proliferation. Interestingly, both cisplatin- and vehicle-treated brain-grown cells had a reduced proliferation and CFE in comparison to the parental C6 cells. Conclusions. Despite numerous reports on the destabilizing effects of cisplatin on genome and phenotype, the cisplatin treatment of C6 cells in vivo did not affect genome stability, CFE, and had an inconsistent effect on the proliferation in vitro. The rat brain microenvironment may potentially impact the growth characteristics of rat glioma cells.
Keywords: aneuploidy, chromosome instability, drug resistance, tumor evolution, heterogeneity.


[1] Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-78.
[2] Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257.
[3] Baklaushev VP, Nukolova NN, Khalansky AS, Gurina OI, Yusubalieva GM, Grinenko NP, Gubskiy IL, Melnikov PA, Kardashova KSh, Kabanov AV, Chekhonin VP. Treatment of glioma by cisplatin-loaded nanogels conjugated with monoclonal antibodies against Cx43 and BSAT1. Drug Deliv. 2015;22(3):276-85.
[4] Nukolova NV, Baklaushev VP, Abakumova TO, Mel'nikov PA, Abakumov MA, Yusubalieva GM, Bychkov DA, Kabanov AV, Chekhonin VP. Targeted delivery of cisplatin by connexin 43 vector nanogels to the focus of experimental glioma C6. Bull Exp Biol Med. 2014;157(4):524-9.
[5] Dorigo O, Turla ST, Lebedeva S, Gjerset RA. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J Neurosurg. 1998;88(3):535-40.
[6] Messina S, Leonetti C, De Gregorio G, Affatigato V, Ragona G, Frati L, Zupi G, Santoni A, Porcellini A. Ras inhibition amplifies cisplatin sensitivity of human glioblastoma. Biochem Biophys Res Commun. 2004;320(2):493-500.
[7] Redjal N, Zhu Y, Shah K. Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors. Stem Cells. 2015;33(1):101-10.
[8] Horne SD, Stevens JB, Abdallah BY, Liu G, Bremer SW, Ye CJ, Heng HH. Why imatinib remains an exception of cancer research. J Cell Physiol. 2013;228(4):665-70.
[9] Stepanenko AA, Kavsan VM. Evolutionary karyotypic theory of cancer versus conventional cancer gene mutation theory. Biopolym Cell. 2012; 28(4):267–80.
[10] Duesberg P, Li R, Sachs R, Fabarius A, Upender MB, Hehlmann R. Cancer drug resistance: the central role of the karyotype. Drug Resist Updat. 2007;10(1-2):51-8.
[11] Stepanenko AA, Kavsan VM. Karyotypically distinct U251, U373, and SNB19 glioma cell lines are of the same origin but have different drug treatment sensitivities. Gene. 2014;540(2):263-5.
[12] Stepanenko A, Andreieva S, Korets K, Mykytenko D, Huleyuk N, Vassetzky Y, Kavsan V. Step-wise and punctuated genome evolution drive phenotype changes of tumor cells. Mutat Res. 2015;771:56-69.
[13] Liu G, Stevens JB, Horne SD, Abdallah BY, Ye KJ, Bremer SW, Ye CJ, Chen DJ, Heng HH. Genome chaos: survival strategy during crisis. Cell Cycle. 2014;13(4):528-37.
[14] Roberts JJ, Friedlos F. Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol Ther. 1987;34(2):215-46.
[15] Brodberg RK, Lyman RF, Woodruff RC. The induction of chromosome aberrations by cis-platinum(II) diamminodichloride in Drosophila melanogaster. Environ Mutagen. 1983;5(3):285-97.
[16] Myung K, Kolodner RD. Induction of genome instability by DNA damage in Saccharomyces cerevisiae. DNA Repair (Amst). 2003;2(3):243-58.
[17] Wasenius VM, Jekunen A, Monni O, Joensuu H, Aebi S, Howell SB, Knuutila S. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer. 1997;18(4):286-91.
[18] Prasad M, Bernardini M, Tsalenko A, Marrano P, Paderova J, Lee CH, Ben-Dor A, Barrett MT, Squire JA. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells. Genes Chromosomes Cancer. 2008;47(5):427-36.
[19] Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706-21.
[20] Gabbiani C, Magherini F, Modesti A, Messori L. Proteomic and metallomic strategies for understanding the mode of action of anticancer metallodrugs. Anticancer Agents Med Chem. 2010;10(4):324-37.
[21] Geissmann Q. OpenCFU, a new free and open-source software to count cell colonies and other circular objects. PLoS One. 2013;8(2):e54072.
[22] Grundei T, Vogelsang H, Ott K, Mueller J, Scholz M, Becker K, Fink U, Siewert JR, H?fler H, Keller G. Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res. 2000;6(12):4782-8.
[23] Heng HH, Liu G, Stevens JB, Bremer SW, Ye KJ, Abdallah BY, Horne SD, Ye CJ. Decoding the genome beyond sequencing: the new phase of genomic research. Genomics. 2011;98(4):242-52.
[24] Galvao J, Davis B, Tilley M, Normando E, Duchen MR, Cordeiro MF. Unexpected low-dose toxicity of the universal solvent DMSO. FASEB J. 2014;28(3):1317-30.
[25] Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB, Hellman R; Eastern Cooperative Oncology Group. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol. 2003;21(8):1485-91. PubMed PMID: 12697871.
[26] Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, O'Fallon JR; North Central Cancer Treatment Group 93-72-52; Southwest Oncology Group 9503 Trials. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin On­col. 2006;24(24):3871–9.
[27] Blumenthal DT, Rankin C, Eyre HJ, Livingston RB, Spence AM, Stelzer KJ, Rushing EJ, Berger MS, Rivkin SE, Cohn AL, Petersdorf SH. External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial. Cancer. 2008;113(3):559-65.
[28] Silvani A, Gaviani P, Lamperti EA, Eoli M, Falcone C, Dimeco F, Milanesi IM, Erbetta A, Boiardi A, Fariselli L, Salmaggi A. Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. J Neurooncol. 2009;94(1):57-62.
[29] Kim IH, Park CK, Heo DS, Kim CY, Rhee CH, Nam DH, Lee SH, Han JH, Lee SH, Kim TM, Kim DW, Kim JE, Paek SH, Kim DG, Kim IA, Kim YJ, Kim JH, Park BJ, Jung HW. Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. J Neurooncol. 2011;103(3):595-602.
[30] D?az R, Jord? MV, Reyn?s G, Aparicio J, Segura A, Amador R, Calderero V, Beltr?n A. Neoadjuvant cisplatin and etoposide, with or without tamoxifen, prior to radiotherapy in high-grade gliomas: a single-center experience. Anticancer Drugs. 2005;16(3):323-9.
[31] Swinnen LJ, Rankin C, Carraway H, Albain KS, Townsend JJ, Budd GT, Kish JA, Rivkin SE, Blumenthal DT. A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest On­co­logy Group S9149). J Neurooncol. 2008;86(3):353–8.
[32] Nageswara Rao AA, Wallace DJ, Billups C, Boyett JM, Ga­jjar A, Packer RJ. Cumulative cisplatin dose is not associated with event-free or overall survival in children with ne­wly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Chi­ldren’s Oncology Group. Pediatr Blood Cancer. 2014; 61(1):102–6.
[33] Duesberg P, Li R, Fabarius A, Hehlmann R. The chromosomal basis of cancer. Cell Oncol. 2005;27(5-6):293-318.
[34] Stepanenko, Kavsan VM. Immortalization and malignant tran­sformation of Eukaryotic cells. Cytol Genet. 2012; 46(2): 96–129.
[35] Stepanenko AA, Vassetzky YS, Kavsan VM. Antagonistic functional duality of cancer genes. Gene. 2013;529(2):199-207.
[36] Stepanenko A, Kavsan V. Cancer genes and chromosome in­stability. In: Oncogene and cancer – from bench to clinic. Rijeka: InTech Publisher, 2013. 496 p.
[37] Stevens JB, Abdallah BY, Liu G, Ye CJ, Horne SD, Wang G, Savasan S, Shekhar M, Krawetz SA, H?ttemann M, Tainsky MA, Wu GS, Xie Y, Zhang K, Heng HH. Diverse system stresses: common mechanisms of chromosome fragmentation. Cell Death Dis. 2011;2:e178.
[38] Duesberg P, Mandrioli D, McCormack A, Nicholson JM. Is carcinogenesis a form of speciation? Cell Cycle. 2011;10(13):2100-14.